Neuvivo, Inc

Biopharmaceutical investors and executives alike conceded during the recent BIO International Convention that the booming financial environment, which peaked in 2020 and 2021 with record levels of ven

Going public has been a lucrative means of raising cash for hundreds of biopharmaceutical companies during the past few years, but with biotech stock valuations plummeting it has become increasingly d

The flow of venture capital into biopharmaceutical companies has been astonishing – breaking the prior record by a wide margin in 2020 – and, so far, 2021 looks like it is on track to leave a big gap

Otonomy, Inc. suffered a significant share price hit on 22 February with a last-gasp Phase III failure for its sustained-exposure formulation of dexamethasone in Meniere’s disease, a rare inner ear d